Data suggests that initiating negative pressure wound therapy with instillation and dwell (NPWTi-d) with Veraflo Therapy within 1 day of NPWT (as opposed to 2-7 days of NPWT application) helped deliver a combination of positive clinical and health economic outcomes, including1*:
Early initiation (within 1 day) of Veraflo Therapy helped improve patient outcomes and reduce care costs versus waiting 2 to 7 days.1*
Infection may start much sooner than we can easily detect. From clean-"looking" yet potentially contaminated wounds to wounds with heavy bioburden and infection, Veraflo Therapy can be used to help manage a wide range of wound types and characteristics.
Recent software and dressing kit upgrades make things easier for everyone involved—surgeons, nurses, and patients. Your 3M account team is always at the ready to train surgeons and nurses in the use of Verao Therapy on Day 1.
NOTE: Specifc indications, contraindications, warnings, precautions, and safety information exist for these products and therapies. Please consult a clinician and product Instructions for Use prior to application. Rx only.
*A retrospective analysis was conducted utilizing a national, all-payer hospital database and included patients who received NPWTi-d (3M™ Veraflo™ Therapy) as an inpatient visit in 2019. A matched cohort of 514 patients who received either early (within 1 day of NPWT application) or late (within 2-7 days of NPWT application) NPWTi-d initiation was created using propensity scoring.
1. Collinsworth AW, Griffn LP. The effect of timing of instillation therapy on outcomes and costs for patients receiving negative pressure wound therapy. Wounds. 2022;34(11):269-275.
The brands listed above are trademarks of 3M.